Peptide Ltd. will continue to support basic and applied research on the use of the Immunokine molecules as well as the Esperanza Homeopathic NeuroPeptide sublingual spray.

Click here if you wish to see our Powerpoint presentation (you must have Microsoft PowerPoint to view this file)

"Peptide Technology" has been patented, (US Patent #5,989,857) therefore permitting the development of hundreds of novel therapeutic proteins for which we have exclusive research rights. Essentially, proteins are taken, and then denatured by chemical modification and novel applications for them to be identified.

Our scientists also have the ability to generate such peptides by genetic engineering and protein synthesis.

So far our scientists have identified six new antiviral compounds, a further three compounds for use in neurological / neuromuscular disorder and others which have demonstrated anti-tumour properties. Other modified proteins are being identified which will have application for the treatment of diabetes, incontinence and muscular dystrophy.

The first of these is a novel peptide supplement, a modified protein derived from a neuroactive anti-cholinergic molecule. Another development is Micro Emulsion Technology (MET), a topical delivery system that is based on glycerine spheres. Glycerine is an FDA approved wound healing agent.

MET alone displays excellent healing properties and is also able to encapsulate small molecules and large proteins providing very stable delivery. We have successfully field-tested our first drug in the delivery format. Antibodies have also been incorporated into this unique system.

Finally, the recent development of a proprietary sublingual, oral delivery format of these unique peptides has eliminated the necessity of patients injecting themselves with protein molecules! While early studies show the format to have an efficiency of over ninety-five percent, long-term MS patients have been enthusiastic since it provides much greater convenience over the injectable format.

This route of administration when combined with the drug's negligible side effects and stability will assist in improved patient compliance when treating such conditions as early HIV infection and AIDS.